Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients
Primary result · Change in LS-BMDResult — go to the resultGroup difference 0.020 g/cm² 95% CI 0.010–0.029Authors' conclusion
Eldecalcitol add-on therapy increased LS-BMD in osteopenic to osteoporotic postmenopausal women treated with an AI and risedronate.
Study context
- Population
- Postmenopausal women with HR + early-stage breast cancer (TNM stage 0–3A) on AI, treated with risedronate for >12 months196 in full analysis set
- Participants
- 200 women
- Comparison
- Eldecalcitol add-on to risedronate vs risedronate monotherapy
- Primary endpoint
- Group difference in change of lumbar spine (LS)-BMD
- Follow-up
- 24 months
Methodological detailsopen-label
- Open-label
Primary result
Change in LS-BMD
Group difference
0.020 g/cm²
95% CI 0.010–0.029
P < 0.001
Add-on therapyvs Monotherapy
group difference 0.020 g/cm² (95% CI 0.010–0.029); P < 0.001
As reported in the abstract
Secondary outcomes
| Outcome | IRR (95% CI) | P value | |
|---|---|---|---|
| Morphometric vertebral fractures | 0.292 (0.080–1.061) | P = 0.061 | |
| 0.050.21520Incidence rate ratio (log scale) |
Change in FN-BMD and TH-BMD · 24 months
- Increase in femoral neck (FN)- and TH-BMD larger with add-on therapy than monotherapy
Change in trabecular bone score (TBS)
- No group difference detected in change in TBS
Original publication
Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients. J Clin Endocrinol Metab. Published 15 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →